Overview

This trial is active, not recruiting.

Condition healthy
Treatments biib023, placebo
Phase phase 1
Sponsor Biogen Idec
Start date October 2013
End date January 2014
Trial size 34 participants
Trial identifier NCT01943513, 211HV103

Summary

The primary objective of this study is to determine whether muscle atrophy induced by immobilization of the lower limb can be attenuated by BIIB023 in healthy male volunteers. The secondary objectives of this study in this study population are:

- To determine whether muscle weakness induced by immobilization of the lower limb can be attenuated by BIIB023

- To assess the effect of BIIB023 on the recovery of muscle mass and strength after immobilization

- To assess the effect of BIIB023 on histological markers of muscle atrophy and regeneration

- To assess the effect of BIIB023 on muscle bioenergetics based on oxidative metabolism recovery kinetics

- To evaluate the safety and tolerability of BIIB023

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
Arm
(Experimental)
Subjects will be randomly assigned to receive intravenous (IV) infusions of BIIB023
biib023 (anti-TWEAK [TNF-related Weak Inducer of Apoptosis] monoclonal antibody)
Intravenous infusion
(Placebo Comparator)
Subjects will be randomly assigned to receive intravenous (IV) infusions of placebo
placebo
Placebo intravenous infusion

Primary Outcomes

Measure
Percentage change in the magnitude of muscle atrophy
time frame: between Day 14 and Day 42

Secondary Outcomes

Measure
Percentage change in the magnitude of muscle atrophy, measured by T1W-MRI analysis of the CSA of the triceps surae muscles of the immobilized limb
time frame: between Day 14 and Day 42
Percentage change in isometric knee-extension strength (torque), measured by dynamometry
time frame: between Day 14 and Day 42
Percentage change in isometric plantar-flexion strength (torque), measured by dynamometry
time frame: between Day 14 and Day 42
Percentage change in total CSA of Type I and II fibers, measured by histological analysis of muscle biopsy
time frame: between Day 14, Day 21, and Day 42
Change in density of satellite cells and other molecular markers of muscle regeneration, measured by histological analysis of muscle biopsy
time frame: between Day 14, Day 21, and Day 42
Change in the recovery of muscle oxidative metabolism, measured by near-infrared spectroscopy (NIRS) of the quadriceps femoris muscles
time frame: between Day 14 and Day 42
The number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)
time frame: Day 156

Eligibility Criteria

Male participants from 18 years up to 35 years old.

Key Inclusion Criteria: - Deemed healthy as determined by the Investigator based on medical history, 12-lead electrocardiogram, vital signs, and clinical laboratory parameters at Screening, and physical examination at Baseline - Body mass index (BMI) between 18.5 and 32 kg/m2, inclusive, at the time of Screening - Willing to abstain from using tobacco and tobacco-containing products during the study - Willing to limit the intake of alcohol to no more than 2 units per day throughout the study; exceptions are 48 hours prior to Screening, 48 hours prior to Day 1, and during the in-clinic immobilization period when no alcohol will be permitted. One unit of alcohol is defined as 12 fluid ounce (fl oz) of beer, 5 fl oz of wine, or 1.5 fl oz of liquor - Willing to maintain a regular diet for the duration of the study and a recreational level of physical activity defined as participation in an exercise program or other physical activity at a level of intensity that does not exceed the level prior to study entry - Practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after the last dose of study treatment. Key Exclusion Criteria: - History of or positive test result at Screening for human immunodeficiency virus (HIV). - History or positive test result at Screening for hepatitis C virus (HCV) antibody or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]). - History of tuberculosis (TB) or a positive QuantiFERON®-TB Gold test. There must be no other clinical evidence of TB on physical examination of the subject. - Use of tobacco or tobacco-containing products within 3 months prior to Screening - Known history of thrombophilia, hypercoagulopathy, or prior history of deep vein thrombosis (DVT) or pulmonary embolism (PE) - History of physical activity consistent with endurance training or resistance training within 6 months prior to Screening - Any back, leg, knee, or shoulder complaints that may interfere with the use of crutches - Prolonged travel (more than 6 hours) within 2 weeks prior to randomization. NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Additional Information

Official title A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Intravenous BIIB023 (Anti-TWEAK) on Lower Limb Muscle Mass and Strength During and After Knee-Joint Immobilization in Healthy Male Volunteers
Trial information was received from ClinicalTrials.gov and was last updated in March 2014.
Information provided to ClinicalTrials.gov by Biogen Idec.